They also were categorized as having no cardiometabolic diseases, a single cardiometabolic disease, or cardiometabolic multimorbidity (CMM; defined as having ≥2 cardiometabolic diseases). Patients with a single cardiometabolic disease or CMM had a 56% (95% CI, 51%-60%) or 152% (95% CI, 140%-165%) increased risk for all-cause mortality, respectively, compared with those without cardiometabolic disease. The prefrail and frailty phenotype-related hazard ratios (HRs) for all-cause mortality were 1.40 (95% CI, 1.37-1.43) and 2.63 (95% CI, 2.51-2.75), respectively, compared with the robust phenotype. Compared with individuals without cardiometabolic disease and frailty at baseline, those with both CMM and frailty phenotype had the highest all-cause and cardiac mortality risk (HR for all-cause mortality, 4.91 [95% CI, 4.49-5.38]; HR for cardiac mortality, 8.33 [95% CI, 7.13-9.72]), with 23% and 36% of the effect sizes, respectively, owing to the additive interaction. The coexistence of CMM and moderate/severe frailty per FI also resulted in the highest risk for all-cause mortality (HR, 3.65; 95% CI, 3.4-3.91) and cardiac mortality (HR, 5.93; 95% CI, 5.24-6.71).